Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24704061 | 0.81 | CYP1A2 (0.42) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL28153615 | 0.76 | CYP1A2 (0.59) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL11848016 | 0.75 | CYP1A2 (0.54) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL11918169 | 0.72 | CYP1A2 (0.50) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL97616 | 0.71 | — | — | |
| SCHEMBL5691762 | 0.71 | CYP1A2 (0.74) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL11853673 | 0.71 | CYP1A2 (0.48) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL22178630 | 0.70 | CYP1A2 (0.53) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL20203309 | 0.69 | CYP1A2 (0.46) | CYP1A2MAPTLMNAMAPK1HTT | |
| SCHEMBL28222077 | 0.69 | CYP1A2 (0.46) | CYP1A2MAPTLMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |